不同剂量氨溴索治疗糖尿病合并社区获得性肺炎的临床观察

目的:观察不同剂量氨溴索治疗糖尿病合并社区获得性肺炎(CAP)的临床疗效和安全性。方法:70例糖尿病合并CAP患者按随机数字表法均分为常规剂量组和双倍剂量组。两组患者均给予口服降糖药、肌肉注射胰岛素等常规治疗。在此基础上,常规剂量组患者给予氨溴索口服液10 ml,bid+盐酸莫西沙星0.4 g加入0.9%氯化钠注射液250 ml中静脉滴注,qd;双倍剂量组患者给予氨溴索口服液20 ml,bid+盐酸莫西沙星(用法用量同常规剂量组)。两组患者疗程均为7 d。观察两组患者的临床疗效、治疗前后临床症状总评分、血糖变化及不良反应发生情况。结果:双倍剂量组患者总有效率显著高于常规剂量组,两组比较差异有统计学意义(P<0.05)。治疗前两组患者临床症状总评分比较,差异无统计学意义(P>0.05);治疗后两组患者临床症状总评分显著低于同组治疗前,且双倍剂量组低于常规剂量组,差异有统计学意义(P<0.05)。两组患者治疗前后血糖、不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:双倍剂量氨溴索治疗糖尿病合并CAP的疗效显著优于常规剂量,安全性较好。

Clinical Observation of Different Dose of Ambroxol in the Treatment of Diabetes Complicating with Com- munity-acquired Pneumonia

OBJECTIVE： To observe clinical efficacy and safety of different dose of ambroxol in the treatment of diabetes com- plicating with community-acquired pneumonia （CAP）. METHODS： 70 patients with diabetes complicating with CAP were random- ly divided into routine dose group and double dose group. Both groups were given hypoglycemic drugs orally, intramuscular injec- tion of insulin and other routine treatment. Routine dose group was additionally given Ambroxol oral solution 10 ml, bid, moxiflox- acin hydrochloride 0.4 g added into 0.9% Sodium chloride injection 250 ml, i.v., qd. Double dose group additionally received Am- broxol oral solution 20 ml, bid, moxifloxacin hydrochloride （same usage and dosage as routine dose group）. Treatment course of 2 groups lasted for 7 d. Clinical efficacies of 2 groups were observed, and total symptom score, blood glucose and ADR were also observed before and after treatment. RESULTS： Total effective rate of double dose group was significantly higher than that of rou- tine dose group; there was statistical significance （P〈0.05）. Total symptom score of 2 groups had no statistical significance before treatment （P〉0.05）. Total symptom scores of 2 groups after treatment were significantly lower than before; the double dose group was lower than the routine dose group; there was statistical significance （P〈0.05）. There was no statistical significance in blood glucose and the incidence of ADR in 2 groups before and after treatment （P〉0.05）. CONCLUSIONS： Therapeutic efficacy of dou- ble dose of ambroxol is significantly better than routine dose in the treatment of diabetes complicating with CAP and also has better safety.